90 related articles for article (PubMed ID: 3135291)
21. Immunomodulating effects in vitro of interleukin-2 and interferon-gamma on human blood and bone marrow mononuclear cells.
Kedar E; Rezai AR; Giorgi JV; Gale RP; Champlin RE; Mitsuyasu RT; Fahey JL
Nat Immun Cell Growth Regul; 1988; 7(1):13-30. PubMed ID: 2896298
[TBL] [Abstract][Full Text] [Related]
22. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system.
Panitch HS; Hirsch RL; Schindler J; Johnson KP
Neurology; 1987 Jul; 37(7):1097-102. PubMed ID: 3110648
[TBL] [Abstract][Full Text] [Related]
23. Monocyte- and natural killer cell-mediated spontaneous cytotoxicity against human noncultured solid tumor cells.
Itoh K; Platsoucas CD; Balch CM
Cell Immunol; 1987 Sep; 108(2):495-500. PubMed ID: 3113744
[TBL] [Abstract][Full Text] [Related]
24. Preclinical studies with prothymosin alpha1 on mononuclear cells from tumor patients.
Eckert K; Grünberg E; Garbin F; Maurer HR
Int J Immunopharmacol; 1997; 19(9-10):493-500. PubMed ID: 9637344
[TBL] [Abstract][Full Text] [Related]
25. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
[TBL] [Abstract][Full Text] [Related]
26. Protection of cultured human monocytes from lymphokine-activated killer-mediated lysis by IFN-gamma.
Blanchard DK; Djeu JY
J Immunol; 1988 Dec; 141(11):4067-73. PubMed ID: 2460557
[TBL] [Abstract][Full Text] [Related]
27. Enhancement of human lymphokine-activated killer cell cytolysis and a method for increasing lymphokine-activated killer cell yields to cancer patients.
Yannelli JR; Thurman GB; Mrowca-Bastin A; Pennington CS; West WH; Oldham RK
Cancer Res; 1988 Oct; 48(20):5696-700. PubMed ID: 3262411
[TBL] [Abstract][Full Text] [Related]
28. Adoptive immunotherapy with activated macrophages grown in vitro from blood monocytes in cancer patients: a pilot study.
Lopez M; Fechtenbaum J; David B; Martinache C; Chokri M; Canepa S; De Gramont A; Louvet C; Gorin I; Mortel O
J Immunother (1991); 1992 Apr; 11(3):209-17. PubMed ID: 1515425
[TBL] [Abstract][Full Text] [Related]
29. Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant gamma-interferon.
Kleinerman ES; Kurzrock R; Wyatt D; Quesada JR; Gutterman JU; Fidler IJ
Cancer Res; 1986 Oct; 46(10):5401-5. PubMed ID: 3093063
[TBL] [Abstract][Full Text] [Related]
30. Antitumor properties of mononuclear cells activated by combined treatment with oxidizing mitogens and interleukin-2: basic and clinical studies.
Novogrodsky A; Stenzel KH
Bull N Y Acad Med; 1989 Jan; 65(1):120-7. PubMed ID: 2605394
[No Abstract] [Full Text] [Related]
31. Fc gamma RI and Fc gamma RII on monocytes and granulocytes are cytotoxic trigger molecules for tumor cells.
Graziano RF; Fanger MW
J Immunol; 1987 Nov; 139(10):3536-41. PubMed ID: 2960735
[TBL] [Abstract][Full Text] [Related]
32. Suppressed cell-mediated immunity and monocyte and natural killer cell activity following allogeneic immunization of women with spontaneous recurrent abortion.
Gafter U; Sredni B; Segal J; Kalechman Y
J Clin Immunol; 1997 Sep; 17(5):408-19. PubMed ID: 9327341
[TBL] [Abstract][Full Text] [Related]
33. Augmentation of natural killer cytotoxicity by alpha or gamma natural and recombinant interferons and interferon inducers. Effect of monocytes.
Platsoucas CD; Fernandes G; Good RA; Gupta S
Int Arch Allergy Appl Immunol; 1986; 79(1):1-7. PubMed ID: 3079737
[TBL] [Abstract][Full Text] [Related]
34. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
35. Induction of interferon-gamma production by human natural killer cells stimulated by hydrogen peroxide.
Munakata T; Semba U; Shibuya Y; Kuwano K; Akagi M; Arai S
J Immunol; 1985 Apr; 134(4):2449-55. PubMed ID: 3919096
[TBL] [Abstract][Full Text] [Related]
36. Immune response induced in small-cell lung cancer by maintenance therapy with interferon gamma.
Pujol JL; Gibney DJ; Su JQ; Maksymiuk AW; Jett JR
J Natl Cancer Inst; 1993 Nov; 85(22):1844-50. PubMed ID: 8230265
[TBL] [Abstract][Full Text] [Related]
37. Recombinant interferons or interleukin-2 increase cytotoxicity by human monocytes and NK cells.
Frey JR; Kamber M; Peck R
Lymphokine Res; 1987; 6(3):215-27. PubMed ID: 3114569
[TBL] [Abstract][Full Text] [Related]
38. Decrease of lymphokine (interleukin-2)-activated killer activity in peripheral blood after administration of natural interferon-gamma.
Yanagawa H; Sone S; Okubo A; Fukuta K; Nishioka Y; Ogura T
Jpn J Clin Oncol; 1990 Dec; 20(4):356-63. PubMed ID: 2126575
[TBL] [Abstract][Full Text] [Related]
39. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
40. Lymphokine-activated killer cell expansion for clinical trials of adoptive immunotherapy with interleukin-2: optimization of the culture technique.
Favrot MC; Coze C; Combaret V; Gaspard M; Colin C; Franks C; Negrier S; Philip I; Philip T
Mol Biother; 1990 Mar; 2(1):32-7. PubMed ID: 2185792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
